

**REMARKS**

Claims 33-41 are pending in the application.

Applicants have added new claims that recite the term "autoimmune inhibitor". Support for this term is found in the specification on page 14, lines 13-23 as well at pages 5, 7, 13 and generally throughout the specification.

The claims recite a receptor in the group of recited autoimmune inhibitors. Support for the inclusion of receptors as autoimmune inhibitors is found in the specification specifically on page 11, line 9, on page 14, lines 19-21 and generally throughout out the specification.

The claims recite the treatment of Acquired Immunodeficiency Disease. Support for this recitation is found in the specification on page 17 and elsewhere in the specification.

Since support for each of the amendments made herein is found in the specification, no new matter has been added to the application.

Entry of these amendments is respectfully requested and favorable examination of this application is respectfully requested at the earliest possible time.

Respectfully submitted,

**SKURKOVICH *et al.***

NOVEMBER 30, 2000  
(Date)

By:

Kathryn Doyle  
**KATHRYN BOYLE, Ph.D., J.D.**  
Registration No. 36,317  
**AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.**  
One Commerce Square  
2005 Market Street - Suite 2200  
Philadelphia, PA 19103  
Telephone: (215) 965-1200  
Direct Dial: (215) 965-1284  
Facsimile: (215) 965-1210  
E-Mail: kdoyle@akingump.com

KD/GHL